跳转至内容
Merck

32236

Supelco

Firocoxib

VETRANAL®, analytical standard

别名:

3-Cyclopropylmethoxy-4-(4-methanesulfonylphenyl)-5,5-dimethyl-5H-furan-2-one

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H20O5S
分子量:
336.40
Beilstein:
8335837
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

analytical standard

质量水平

产品线

VETRANAL®

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
veterinary

包装形式

neat

SMILES字符串

O=S(C1=CC=C(C2=C(OCC3CC3)C(OC2(C)C)=O)C=C1)(C)=O

InChI

1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3

InChI key

FULAPETWGIGNMT-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

推荐产品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

法律信息

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Laura T Letendre et al.
American journal of veterinary research, 69(11), 1399-1405 (2008-11-05)
To determine pharmacokinetic parameters and variables, firocoxib concentrations in urine and plasma, urine-to-plasma ratios, and the urine depletion profile of firocoxib and to evaluate whether the pharmacokinetic behavior of firocoxib was governed by linear processes after multiple doses of firocoxib
A Autefage et al.
The Veterinary record, 168(23), 617-617 (2011-06-07)
Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal
W Back et al.
Equine veterinary journal, 41(3), 309-312 (2009-05-28)
Lameness is a highly prevalent condition in horses and the principal cause of removal from athletic activity. In clinical studies to evaluate nonsteroidal anti-inflammatory drug therapies, force plates are commonly used to assess improvement of lameness objectively. To use a
Vanessa L Cook et al.
American journal of veterinary research, 70(8), 992-1000 (2009-08-04)
To determine whether treatment of horses with firocoxib affects recovery of ischemic-injured jejunum, while providing effective analgesia. 18 horses. Horses (n = 6 horses/group) received saline (0.9% NaCl) solution (1 mL/50 kg, IV), flunixin meglumine (1.1 mg/kg, IV, q 12
William G Ryan et al.
Veterinary therapeutics : research in applied veterinary medicine, 8(4), 263-271 (2008-01-10)
Veterinarians currently have a choice of six registered NSAIDs for use in the management of canine osteoarthritis. There is a need for data to clarify whether there is an increased risk of side effects occurring in the event of a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门